AnalystsSteve BrozakSteve Brozak's Stock Forecasts
AnalystsSteve Brozak
Sectors:
Analyst Ranking
Bottom 9%
#4212 out of 4577 analysts
Average Return
-52.65%
Win Rate
0%0 out of 8
Risk vs Reward
Poor
Good
Steve Brozak's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
No Ratings AvailableSteve Brozak doesn't have any winning ratings in our database | |||||
Steve Brozak Analyst Color
Get additional color on Steve Brozak's coverage of popular stocks
Steve Brozak's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Contrafect CorpCFRXQ | 2 | Strong Buy | $560.00 | N/A | Upgrades | 2 years ago |
Paratek Pharmaceuticals IncPRTK | 1 | Strong Buy | $11.00 | N/A | Upgrades | 2 years ago |
Cidara Therapeutics IncCDTX | 1 | Strong Buy | N/A | N/A | Upgrades | 3 years ago |
Omeros CorpOMER | 1 | Strong Buy | $100.00 | N/A | Maintains | 3 years ago |
Redhill Biopharma LtdRDHL | 2 | Buy | $640.00 | N/A | Downgrades | 3 years ago |
Cohbar IncCWBR | 1 | Buy | $135.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.